Edgar Filing: Schrepfer Robert W - Form 4

Schrepfer R Form 4 March 05, 2											
FORM	ЛЛ								OMB AF	PROVAL	
	UNITE	RITIES A shington,			NGE C	OMMISSION	OMB Number:	3235-0287			
Check the if no lon subject to Section Form 4	nger STAT to STAT 16. or	EMENT O	Expires: January 31 200 Estimated average burden hours per response 0.								
Form 5 obligatio may cor See Inst 1(b). (Print or Type	ntinue. Section	7(a) of the	Public U		ling Com	ipany	Act of	e Act of 1934, 1935 or Sectior 0	1		
Schrepfer Robert W Symbol				er Name and Ticker or Trading HARMACEUTICALS INC]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				h				Director 10% Owner _X_ Officer (give title Other (specify below) SVP - New Bus Dev & Spec Sales			
	(Street) TE, MN 56623			endment, Da nth/Day/Year	-			6. Individual or Jo Applicable Line) _X_ Form filed by C Form filed by M	one Reporting Pe	rson	
(City)	(State)	(Zip)	Tabl	La L. Mara D	· · · · · · · · · · · · · · · · · · ·		4	Person	an Dan official	ha Orana d	
1.Title of Security (Instr. 3)		ransaction Date 2A. Deemed			(A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Common Stock	03/01/2018			Code V M	18,750	A	\$ 28.76	41,590	D		
Common Stock	03/01/2018			S	5,498	D	\$ 60.33 (1)	36,092	D		
Common Stock	03/01/2018			S	10,800	D	\$ 61.64 (2)	25,292	D		
Common Stock	03/01/2018			S	11,954	D	\$ 62.25	13,338	D		

Edgar Filing: Schrepfer Robert W - Form 4

					(3)		
Common Stock	03/01/2018	S	400	D	\$ 63.07	12,938	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities8(Instr. 3 and 4)S(1)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 28.76	03/01/2018		М	18,750	(4)	08/19/2024	Common Stock	18,750

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Schrepfer Robert W C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST BAUDETTE, MN 56623			SVP - New Bus Dev & Spec Sales				
Signatures							
Signatures							

/s/ Robert Schrepfer 03/05/2018 <u>**</u>Signature of Date Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This transaction was executed in multiple trades at prices ranging from \$60.00 to \$60.98. The price reported above reflects the weighted
 (1) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Edgar Filing: Schrepfer Robert W - Form 4

This transaction was executed in multiple trades at prices ranging from \$61.00 to \$61.97. The price reported above reflects the weighted
 (2) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from \$62.00 to \$62.95. The price reported above reflects the weighted(3) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(4) The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date of the options was August 20, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.